Under the strict fight against illegal and illegal activities, how should the operating mode of pharmaceutical companies be transformed?

"Pharmaceutical Network Market Analysis" In recent years, some pharmaceutical companies involved in financial fraud, insider trading and other illegal violations are frequently reported, high marketing costs have caused a lot of controversy.
recently, the state held an executive meeting on the further improvement of the quality of listed companies, aimed at protecting the rights and interests of investors, to promote the sustained, stable and healthy development of the capital market.
fact, the state decided to crack down on capital markets and crack down on illegal and illegal activities.
can be said to be from the national level and all levels of pharmaceutical regulatory departments around the industry enterprises compliance, legitimate business requirements, no doubt released a new regulatory signal.
To this, some analysts in the pharmaceutical industry believe that China's pharmaceutical industry is also at a key node in the transformation, forcing the industry to purify and upgrade is an important industrial development goal, in the scientific approval, medical insurance control fees, volume procurement, compliance supervision and other policies hit the combination of fists, the relevant departments issued regulatory measures are ring-linking, which will also lead to the past drug companies traditional simple rough management, operation and sales model will be unsustainable.
in this case, how should the operation and marketing model of pharmaceutical companies be transformed? Industry experts said that product upgrading is an important path for pharmaceutical companies to achieve transformation, after all, marketing needs product support.
There are three main routes, first, like Hengrui Pharmaceuticals, Qilu Pharmaceuticals and other companies, to take the Path of Big Pharma (large pharmaceutical companies) for independent research and development;
, due to the very large investment required for independent research and development, coupled with the difficulty of some varieties of independent research and development, the license-in model and the model of the combination of imitation will be more convenient and effective for most enterprises.
fact, in addition to product upgrading, the state strict control, as well as vigorously develop the Internet plus era at present, domestic pharmaceutical companies are increasingly aware of the importance of digital transformation.
According to the data, since this year, the major pharmaceutical companies in the digital construction of investment significantly increased, in 2019 digital-related costs accounted for more than 10% of the total cost of product investment of pharmaceutical companies accounted for 23%, and in March 2020, this figure rose rapidly to 40%, is expected to later or maintain 38%.
It is worth noting, however, that while pharmaceutical companies are making their way to digitalization, in the process of embracing digitalization, many pharmaceutical companies have problems such as lack of top-level design, insufficient impetus, information silos, weak IT management, and so on, and need to find a breakthrough.
, there is a view in the industry that marketing digitalization is equal to the traditional information technology and "Internet" and offline resources integration, not simply divesting the two markets, the future needs to rise to a higher strategic level to plan.
Overall, under the new situation, the pharmaceutical industry to pollution, low-standard drugs, commercial bribery, extensive operation and to go to the box restrictions will become more and more clear, improve research and development capabilities, improve drug production standards, enhance drug production capacity, improve the operating capacity of pharmaceutical companies and enhance industry concentration will become the mainstream trend, and pharmaceutical companies can only adapt to the current situation to have more opportunities for development.